Mga Batayang Estadistika
| CIK | 1785530 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Werewolf Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 14, 2025 |
a06302025ex992 ©2025 WEREWOLF THERAPEUTICS1 | CORPORATE PRESENTATION | August 2025 Building a Novel Class of Conditionally Activated Immunotherapies for Patients with Cancer ©2025 WEREWOLF THERAPEUTICS2 | Cautionary Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| August 14, 2025 |
Employment Agreement dated as of April 3, 2025, by and between the Registrant and Steven Bloom. Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of April 3rd, 2025, by and between Werewolf Therapeutics, Inc. (the “Company”), and Steven Bloom (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Business Officer; WHEREAS, the Executive has agreed to accept employment with the Company on |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-40 |
|
| August 14, 2025 |
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update – WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in |
|
| June 13, 2025 |
EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 2 1.8 Adjournments 2 1.9 Voting and Proxies 3 1.10 Action at Meeting 3 1.11 Nomination of Directors 4 1 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 13, 2025 |
WEREWOLF THERAPEUTICS, INC. 200 Talcott Avenue, 2nd Floor Watertown, MA 02472 WEREWOLF THERAPEUTICS, INC. 200 Talcott Avenue, 2nd Floor Watertown, MA 02472 May 13, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Werewolf Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-287078 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated |
|
| May 8, 2025 |
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update – WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 8, 2025 |
a03312025ex992 ©2025 WEREWOLF THERAPEUTICS1 | Delivering the Power of Immunotherapy CORPORATE PRESENTATION | May 2025 ©2025 WEREWOLF THERAPEUTICS2 | Cautionary Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| May 8, 2025 |
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| May 8, 2025 |
Sales Agreement, dated as of May 10, 2022, by and between the Registrant and Leerink Partners LLC Exhibit 1.2 WEREWOLF THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 10, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuanc |
|
| May 8, 2025 |
Form of Inducement Stock Option Agreement. EX-99.1 Exhibit 99.1 Werewolf Therapeutics, Inc. Form of Inducement Stock Option Agreement 1. Grant of Option. This agreement evidences the grant by Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), on [] (the “Grant Date”) to [] (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein, a total of [] shares (the “Shares”) of common stock, |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 S-8 As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
Exhibit 4.3 WEREWOLF THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Werewolf Therapeutics, Inc. |
|
| May 8, 2025 |
Calculation of Filing Fee Tables. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Werewolf Therapeutics, Inc. |
|
| May 8, 2025 |
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-4 |
|
| May 8, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.1 WEREWOLF THERAPEUTICS, INC. DIRECTOR COMPENSATION POLICY The non-employee directors of Werewolf Therapeutics, Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company. 1.Initial Stock Option Grant. Upon initial election to the Board, each non-employee director will be granted, automatically and wi |
|
| May 8, 2025 |
Form of Subordinated Indenture Exhibit 4.4 WEREWOLF THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| March 11, 2025 |
As filed with the Securities and Exchange Commission on March 11, 2025 As filed with the Securities and Exchange Commission on March 11, 2025 Registration No. |
|
| March 11, 2025 |
Exhibit 19 WEREWOLF THERAPEUTICS, INC. Insider Trading Policy 1.BACKGROUND AND PURPOSE 1.1Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Werewolf Therapeutics, Inc. (together with its |
|
| March 11, 2025 |
Exhibit 10.21 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of December 31, 2024, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and WEREWOLF THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS WHEREAS, Landlord and Tenant are parties to that certain Lease Agreement dated as of June 1, 2021, as a |
|
| March 11, 2025 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Werewolf Therapeutics, Inc. |
|
| March 11, 2025 |
Exhibit 99.1 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update –Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively - –Plan to meet with the FDA in the |
|
| March 11, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.22 WEREWOLF THERAPEUTICS, INC. DIRECTOR COMPENSATION POLICY The non-employee directors of Werewolf Therapeutics, Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company. 1.Initial Stock Option Grant. Upon initial election to the Board, each non-employee director will be granted, automatically and w |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 11, 2025 |
Up to $14,437,740 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-264844 AMENDMENT NO. 1 To Prospectus Supplement dated February 9, 2024 (To Prospectus dated May 20, 2022) Up to $14,437,740 Common Stock This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends and supplements the information in the prospectus, dated May 20, 2022, filed as part of our registration statement on Form S-3 (File No. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-4036 |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 14, 2024 |
HOWL / Werewolf Therapeutics, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* WEREWOLF THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 95075A107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 14, 2024 |
HOWL / Werewolf Therapeutics, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427962d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 13, 2024 |
HOWL / Werewolf Therapeutics, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d10sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Chec |
|
| November 12, 2024 |
Exhibit 99.1 Delivering the Power of Immunotherapy CORPORATE PRESENTATION | November 2024 1 | ©2024 WEREWOLF THERAPEUTICS Cautionary Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties inherent in the development of product candidates, including the conduct uncertainties. All statements, other than statements of historical facts, contai |
|
| November 12, 2024 |
SC 13G/A 1 p24-3023sc13ga.htm WEREWOLF THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 0 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 7, 2024 |
Exhibit 99.1 Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update –Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – –Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy d |
|
| November 7, 2024 |
Exhibit 99.2 Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting –Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals – –Additional preclinical data demonstrate INDUKINETM molecules’ anti |
|
| August 8, 2024 |
LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 2, 2024 (the “Closing Date”) is entered into among WEREWOLF THERAPEUTICS, INC. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-40 |
|
| August 8, 2024 |
Form of Common Stock Purchase Warrant. THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. |
|
| August 8, 2024 |
Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update –Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – –Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – –Updated data on WTX-124 in comb |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 8, 2024 |
Registration No. 333-270764 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Werewolf Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-3523180 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No. |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 25, 2024 |
Exhibit 99.1 Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over his |
|
| June 3, 2024 |
EX-99.2 Exhibit 99.2 Shifting the Balance in Cytokine Therapeutics ASCO 2024 WTX-124 Phase 1/1b Clinical Trial Update Investor Webcast June 3, 2024 ©2024 WEREWOLF THERAPEUTICS Cautionary Note Regarding Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties inherent in the development of product candidates, in |
|
| June 3, 2024 |
EX-99.1 Exhibit 99.1 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective r |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 7, 2024 |
HOWL / Werewolf Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2413791d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-4 |
|
| May 3, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 3, 2024 |
Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update –Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — –Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — –Mu |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 7, 2024 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Werewolf Therapeutics, Inc. |
|
| March 7, 2024 |
Exhibit 97 WEREWOLF THERAPEUTICS, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Werewolf Therapeutics, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-4036 |
|
| March 7, 2024 |
Exhibit 99.1 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update –Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 - –WTX-124 recommended dose for expansion (RDE), initiation of monotherapy dose expansion arms and initial combination dose-escala |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| March 7, 2024 |
Exhibit 10.22 WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT Werewolf Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: Vesti |
|
| February 14, 2024 |
HOWL / Werewolf Therapeutics, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm245198d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) |
|
| February 14, 2024 |
HOWL / Werewolf Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm246242d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, |
|
| February 13, 2024 |
HOWL / Werewolf Therapeutics, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 95075A107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 12, 2024 |
HOWL / Werewolf Therapeutics, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d8sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check t |
|
| February 9, 2024 |
Up to $25,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264844 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2022) Up to $25,000,000 Common Stock We previously entered into a sales agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock, par value $0.0001 per share. In accordance with the terms of th |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 8, 2024 |
Exhibit 99.2 Shifting the Balance in Cytokine Therapeutics Corporate Overview | January 2024 Cautionary Statements This presentation contains forward-looking statements that involve substantial risks and important factors, including: uncertainties inherent in the development of product uncertainties. All statements, other than statements of historical facts, contained in this candidates, including |
|
| January 8, 2024 |
Exhibit 99.1 Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook - Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 - - WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data from Phase 1/1b clinical trial expected in 1H 2024 - |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 21, 2023 |
SC 13G 1 p23-2991sc13g.htm WEREWOLF THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) December 11, 2023 (Date of Event Which Requires Filing of This Statemen |
|
| November 14, 2023 |
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update –Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – –Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 0 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employ |
|
| November 3, 2023 |
Exhibit 99.1 Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting - Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or |
|
| November 3, 2023 |
SITC 2023 WTX-124 Phase 1/1b Clinical Trial Preliminary Data Overview Investor Webcast November 3, 2023 Shifting the Balance in Cytokine Therapeutics ©2023 WEREWOLF THERAPEUTICS Exhibit 99. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employe |
|
| September 18, 2023 |
Corporate Overview | September 2023 Shifting the Balance in Cytokine Therapeutics Exhibit 99. |
|
| September 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 10, 2023 |
Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 - - Phase 1 clinical trial for IL-12 INDUKINE WTX-330 progressing in patien |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-40 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 27, 2023 |
EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 4 1.1 Place of Meetings 4 1.2 Annual Meeting 4 1.3 Special Meetings 4 1.4 Record Date for Stockholder Meetings 4 1.5 Notice of Meetings 4 1.6 Voting List 5 1.7 Quorum 5 1.8 Adjournments 5 1.9 Voting and Proxies 6 1.10 Action at Meeting 6 1.11 Nomination of Directors 6 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-4 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 11, 2023 |
Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 - - Progressing Phase 1 clinical trial for IL-12 INDUKINE WTX-330 in patients with advanced |
|
| April 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| March 23, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-4036 |
|
| March 23, 2023 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Werewolf Therapeutics, Inc. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 23, 2023 |
Exhibit 99.1 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors- -Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patients with advanced or |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 22, 2023 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This First Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is made and entered into as of March 16, 2023, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and WEREWOLF THERAPEUTICS, INC. (“Borrower”). RECITALS Borrower and Bank are parties to tha |
|
| February 10, 2023 |
HOWL / Werewolf Therapeutics, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| January 17, 2023 |
HOWL / Werewolf Therapeutics, Inc. / PFM Health Sciences, LP - SC 13G Passive Investment SC 13G 1 tm233627d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) Janua |
|
| January 17, 2023 |
EX-99.1 2 tm233627d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Werewolf Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act |
|
| January 17, 2023 |
HOWL / Werewolf Therapeutics, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) December 31, 2022 (Date of Event Which R |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 10, 2023 |
HOWL / Werewolf Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Pe |
|
| November 10, 2022 |
Exhibit 99.1 Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Dosed first patient in Phase 1/1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in advanced solid tumors; initial data anticipated in the fourth quarter of 2023 - - FDA granted clearance of investigational new drug (IND) application for WTX-33 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employ |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 0 |
|
| September 7, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| September 7, 2022 |
Letter from Deloitte & Touche LLP, dated September 7, 2022. Exhibit 16.1 Deloitte & Touche LLP 200 Berkeley Street Boston, MA 02116 USA Tel: 1 617 437 2000 Fax: 1 617 437 2111 www.deloitte.com September 7, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Werewolf Therapeutics Inc?s Form 8-K dated September 7, 2022, and we agree with the statements made in paragraphs 2, 3, 4, |
|
| August 12, 2022 |
HOWL / Werewolf Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Numbe |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-40 |
|
| August 11, 2022 |
Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights - FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for WTX-330 planned in 2H22 - - Q2 cash and cash equivalents balance of $145.7 million provides runway through at least the fourth quarter of |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 18, 2022 |
WEREWOLF THERAPEUTICS, INC. 1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138 CORRESP 1 filename1.htm WEREWOLF THERAPEUTICS, INC. 1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138 May 18, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Werewolf Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-264844 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 prom |
|
| May 10, 2022 |
Form of Subordinated Indenture Exhibit 4.5 WEREWOLF THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3 |
|
| May 10, 2022 |
Sales Agreement, dated as of May 10, 2022, by and between the Registrant and SVB Securities LLC Exhibit 1.2 WEREWOLF THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 10, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1. Issuanc |
|
| May 10, 2022 |
Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights - Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront payment and eligibility for up to $1.26B in downstream milestones as well as royalties on potential future sales - - Presented promising |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-4 |
|
| May 10, 2022 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| May 10, 2022 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| May 10, 2022 |
Exhibit 4.4 WEREWOLF THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| May 10, 2022 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT by and between Jazz Pharmaceuticals Ireland Limited and Werewolf Therapeutics, Inc. Dated as of April 6, 2022 Confidential |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Werewolf Therapeutics, Inc. |
|
| May 2, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Werewolf Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of t |
|
| May 2, 2022 |
HOWL / Werewolf Therapeutics, Inc. / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) April 21, 2022 (Date of Event Which Requi |
|
| April 22, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permit |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? De |
|
| April 15, 2022 |
Exhibit 10.1 WEREWOLF THERAPEUTICS, INC. AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (the ?Agreement?) is entered into as of April 12, 2022, by and between PACIFIC WESTERN BANK, a California state chartered bank (?Bank?) and WEREWOLF THERAPEUTICS, INC. (collectively with each of the other Persons, if any, that join as a co-Borrower hereund |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 7, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 24, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Werewolf Therapeutics, Inc. |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 S-8 1 a03242022-s8.htm S-8 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WEREWOLF THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-3523180 (State or Other Jurisdiction of Incorpor |
|
| March 24, 2022 |
Exhibit 99.1 Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted anti-tumor immune resp |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-4036 |
|
| March 24, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of Werewolf Therapeutics, Inc. (?us,? ?our,? ?we? or the ?Company?) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), is intended as a summary only and therefore is not a complete descript |
|
| February 11, 2022 |
HOWL / Werewolf Therapeutics, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 0 |
|
| November 10, 2021 |
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 30th, 2021 by and between Werewolf Therapeutics, Inc. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employ |
|
| November 10, 2021 |
Exhibit 99.1 Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- Cambridge, Mass., November 10, 2021 ? Werewolf Therapeutics, Inc. (the ?Company? or ?Werewolf?) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employe |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-40 |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 12, 2021 |
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update Cambridge, Mass., August 12, 2021 ? Werewolf Therapeutics, Inc. (the ?Company? or ?Werewolf?) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body?s immune system for the treatment of cancer, toda |
|
| June 16, 2021 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. Commission File Number 001-4 |
|
| June 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| June 10, 2021 |
Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2021 Financial Results - Recently completed upsized initial public offering raising $120.0 million in gross proceeds - Cambridge, Mass., June 10, 2021 ? Werewolf Therapeutics, Inc. (the ?Company? or ?Werewolf?) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineere |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| June 2, 2021 |
Execution Version LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 1st day of June, 2021, between ARE-MA REGION NO. |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 14, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| May 14, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 95075A107 (CUSIP Number) Ansbert Gadicke MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Num |
|
| May 14, 2021 |
Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Werewolf Therapeutics, Inc. |
|
| May 14, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* WEREWOLF THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 95075A107 (CUSIP Number) May 4, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (C |
|
| May 10, 2021 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Werewolf Therapeutics, Inc. Each of them is responsible for the |
|
| May 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES ACT OF 1934 (Amendment No. ) Werewolf Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share 95075A107 (Title of class of securities) (CUSIP number) Arkin Bio Ventures 2 L.P. 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel Attn: Moshe Arkin Telephone: 972-972-9-7883330 with a copy to |
|
| May 10, 2021 |
Exhibit 5 Arkin Bio Ventures GPGP Ltd. (the ?Company?) Written Consent of the Sole Director of the Company May 10, 2021 RESOLVED THAT: Mr. Moshe Arkin shall have the full power and authority, on behalf of the Company, to prepare, execute, acknowledge, deliver and file a Schedule 13D (including any amendments thereto) and/or a Schedule 13G (including any amendments thereto) with respect to securiti |
|
| May 10, 2021 |
EX-99 3 exhibit3.htm EXHIBIT 3 Exhibit 3 Lock-up Agreement , 2021 Jefferies LLC SVB Leerink LLC Evercore Group L.L.C. As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 and c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 RE: Werewolf Therapeutics, Inc |
|
| May 6, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Werewolf Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 95075A107 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, |
|
| May 5, 2021 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF WEREWOLF THERAPEUTICS, INC. Werewolf Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Werewolf Therapeutics, Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the |
|
| May 5, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 2 1.8 Adjournments 3 1.9 Voting and Proxies 3 1.10 Action at Meeting 3 1.11 Nomination of Directors 4 1.12 Notice of |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 Werewolf Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40366 82-3523180 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| April 30, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-255132 PROSPECTUS 7,500,000 Shares Common Stock We are offering 7,500,000 shares of common stock. This is our initial public offering of our common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $16.00 per share. Our common stock has been approved for listing |
|
| April 30, 2021 |
As filed with the Securities and Exchange Commission on April 30, 2021 Registration No. |
|
| April 29, 2021 |
S-1MEF 1 d160351ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on April 29, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WEREWOLF THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-3523180 (State or other jurisdiction |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Werewolf Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3523180 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1030 Massachuset |
|
| April 27, 2021 |
April 27, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 27, 2021 |
Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138 April 27, 2021 Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138 April 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Werewolf Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-255132 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 |
|
| April 26, 2021 |
Exhibit 10.4 WEREWOLF THERAPEUTICS, INC. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2021 Stock Incentive Plan (the ?Plan?) of Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Co |
|
| April 26, 2021 |
Exhibit 10.7 WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT Werewolf Therapeutics, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of restricted stock units (?RSUs?) granted: Vestin |
|
| April 26, 2021 |
Exhibit 10.8 WEREWOLF THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of this 2021 Employee Stock Purchase Plan (this ?Plan?) is to provide eligible employees of Werewolf Therapeutics, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $0.0001 par value per share (the ?Common Stock?), commencing at such time an |
|
| April 26, 2021 |
. ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# Exhibit 4.1 COMMON STOCK COMMON STOCK PAR VALUE $0.0001 Certificate Shares Number * * 000000 ****************** * * * 000000 ***************** ZQ00000000 **** 000000 **************** WEREWOLF THERAPEUTICS, INC. ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David S |
|
| April 26, 2021 |
Exhibit 10.17 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Cynthia Seidel-Dugan (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); WHER |
|
| April 26, 2021 |
Exhibit 10.18 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Reid Leonard (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); WHEREAS, the |
|
| April 26, 2021 |
Exhibit 10.19 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Ellen Lubman (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); WHEREAS, the |
|
| April 26, 2021 |
Exhibit 10.5 WEREWOLF THERAPEUTICS, INC. STOCK OPTION AGREEMENT Werewolf Therapeutics, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the |
|
| April 26, 2021 |
Exhibit 10.6 WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT Werewolf Therapeutics, Inc. (the ?Company?) hereby grants the following award of restricted stock pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of shares of the restricted common stock, $0.0001 pa |
|
| April 26, 2021 |
Exhibit 10.15 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Daniel J. Hicklin, Ph.D. (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); |
|
| April 26, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 26, 2021 Registration No. |
|
| April 26, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 [?] Shares WEREWOLF THERAPEUTICS, INC. UNDERWRITING AGREEMENT [?], 2021 Jefferies LLC SVB Leerink LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 and c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Ladies and G |
|
| April 26, 2021 |
Exhibit 10.16 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Randi Isaacs (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); WHEREAS, the |
|
| April 26, 2021 |
Exhibit 3.5 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF WEREWOLF THERAPEUTICS, INC. Werewolf Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: A resolution was duly adopted by the Boar |
|
| April 26, 2021 |
Exhibit 10.20 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of April 23, 2021 by and between Werewolf Therapeutics, Inc. (the ?Company?), and Tim Trost (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company has filed a registration statement relating to the proposed initial public offering of the Company?s common stock (the ?IPO?); WHEREAS, the Co |
|
| April 8, 2021 |
EX-10.3 9 d41037dex103.htm EX-10.3 Exhibit 10.3 WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 20[ ], between Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”). For valuable consideration, receipt of which is acknowledged, the |
|
| April 8, 2021 |
Exhibit 10.10 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of , 20 by and between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. [[Solely with respect to officers and d |
|
| April 8, 2021 |
Exhibit 10.2 WEREWOLF THERAPEUTICS, INC. STOCK OPTION AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Stock Option Agreement (this ?Agreement?) is made between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Participant pursuant to the 2017 Stock Incentive Plan (the ?Plan?). NOTICE OF GRANT I. Participant Information Participant: Participant Address: II. Grant I |
|
| April 8, 2021 |
Exhibit 4.2 WEREWOLF THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT DECEMBER 23, 2020 TABLE OF CONTENTS Page 1.???Definitions 1 2.???Registration Rights 6 2.1??Demand Registration 6 2.2??Company Registration 7 2.3??Underwriting Requirements 8 2.4??Obligations of the Company 9 2.5??Furnish Information 10 2.6??Expenses of Registration 11 2.7??Delay of Registration 11 2.8??Indemn |
|
| April 8, 2021 |
April 8, 2021 Rosemary G. Reilly +1 617 526 6633 (t) +1 617 526 5000 (f) wilmerhale.com [email protected] By Electronic Submission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Abby Adams Re: Werewolf Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted February 26, 2021 CIK No. 0001785530 La |
|
| April 8, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 8, 2021 Registration No. |
|
| April 8, 2021 |
Exhibit 21.1 Subsidiaries of the Registrant Werewolf Therapeutics Mass Securities, Inc. |
|
| April 8, 2021 |
Exhibit 10.12 AMENDED AND RESTATED ROYALTY TRANSFER AGREEMENT This Amended and Restated Royalty Transfer Agreement (the ?Agreement?) is made and entered into on August 2, 2019 (the ?Effective Date?), by and between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), MPM Oncology Impact Fund Charitable Foundation, Inc., a Massachusetts charitable foundation (the ?MPM Charitable Fou |
|
| April 8, 2021 |
Exhibit 10.11 EXECUTION COPY Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SECOND AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENT This Second Amended and Restated Assignment and License Agreement (this ?Agreement?) is e |
|
| April 8, 2021 |
Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF WEREWOLF THERAPEUTICS, INC. Werewolf Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Werewolf Therapeutics, Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the |
|
| April 8, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 2 1.8 Adjournments 3 1.9 Voting and Proxies 3 1.10 Action at Meeting 3 1.11 Nomination of Directors 3 1.12 Notice of |
|
| April 8, 2021 |
Exhibit 10.9 LEASE 1030 MASSACHUSETTS AVENUE CAMBRIDGE 1030 MASS AVE, LLC a Delaware limited liability company as Landlord, and WEREWOLF THERAPEUTICS, INC. a Delaware corporation as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 1 1.1 Premises, Building, Project and Common Areas 1 1.2 Stipulation of Rentable Square Feet of Premises 2 1.3 Intentionally Omitted 2 2. |
|
| April 8, 2021 |
Exhibit 10.1 2017 STOCK INCENTIVE PLAN OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS PAGE 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 2 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Price 3 (d) Duration |
|
| April 8, 2021 |
Exhibit 10.14 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 3 day of March, 2021, between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company (?Landlord?), and WEREWOLF THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 480 Arsenal Way, Watertown, Massachusetts Premises: That portion of the Building commonly known as Suite 125, containing approximatel |
|
| April 8, 2021 |
Exhibit 3.2 BYLAWS OF WEREWOLF THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 G |
|
| April 8, 2021 |
EX-10.13 14 d41037dex1013.htm EX-10.13 Exhibit 10.13 WEREWOLF THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of May 29, 2020, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and WEREWOLF THERAPEUTICS, INC. (collectively with each of the other Persons, if any, that join as a co-Borrower hereunder a |
|
| April 8, 2021 |
Second Amended and Restated Certificate of Incorporation of Registrant, as amended. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF WEREWOLF THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Werewolf Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERT |
|
| February 26, 2021 |
WEREWOLF THERAPEUTICS, INC. STOCK OPTION AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN Exhibit 10.2 WEREWOLF THERAPEUTICS, INC. STOCK OPTION AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Stock Option Agreement (this ?Agreement?) is made between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Participant pursuant to the 2017 Stock Incentive Plan (the ?Plan?). NOTICE OF GRANT I. Participant Information Participant: Participant Address: II. Grant I |
|
| February 26, 2021 |
WEREWOLF THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT DECEMBER 23, 2020 Exhibit 4.2 WEREWOLF THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT DECEMBER 23, 2020 TABLE OF CONTENTS Page 1.???Definitions 1 2.???Registration Rights 6 2.1??Demand Registration 6 2.2??Company Registration 7 2.3??Underwriting Requirements 8 2.4??Obligations of the Company 9 2.5??Furnish Information 10 2.6??Expenses of Registration 11 2.7??Delay of Registration 11 2.8??Indemn |
|
| February 26, 2021 |
SECOND AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENT Exhibit 10.11 EXECUTION COPY Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SECOND AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENT This Second Amended and Restated Assignment and License Agreement (this ?Agreement?) is e |
|
| February 26, 2021 |
AMENDED AND RESTATED ROYALTY TRANSFER AGREEMENT Exhibit 10.12 AMENDED AND RESTATED ROYALTY TRANSFER AGREEMENT This Amended and Restated Royalty Transfer Agreement (the ?Agreement?) is made and entered into on August 2, 2019 (the ?Effective Date?), by and between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), MPM Oncology Impact Fund Charitable Foundation, Inc., a Massachusetts charitable foundation (the ?MPM Charitable Fou |
|
| February 26, 2021 |
BYLAWS WEREWOLF THERAPEUTICS, INC. (a Delaware corporation) Exhibit 3.2 BYLAWS OF WEREWOLF THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 G |
|
| February 26, 2021 |
WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN Exhibit 10.3 WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Restricted Stock Agreement (the ?Agreement?) is made this [ ] day of [ ], 20[ ], between Werewolf Therapeutics, Inc., a Delaware corporation (the ?Company?), and [ ] (the ?Participant?). For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 1 |
|
| February 26, 2021 |
Exhibit 10.9 LEASE 1030 MASSACHUSETTS AVENUE CAMBRIDGE 1030 MASS AVE, LLC a Delaware limited liability company as Landlord, and WEREWOLF THERAPEUTICS, INC. a Delaware corporation as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 1 1.1 Premises, Building, Project and Common Areas 1 1.2 Stipulation of Rentable Square Feet of Premises 2 1.3 Intentionally Omitted 2 2. |
|
| February 26, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF WEREWOLF THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Werewolf Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERT |
|
| February 26, 2021 |
As confidentially submitted to the Securities and Exchange Commission on February 26, 2021 Table of Contents As confidentially submitted to the Securities and Exchange Commission on February 26, 2021 Registration No. |
|
| February 26, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Werewolf Therapeutics Mass Securities, Inc. |
|
| February 26, 2021 |
WEREWOLF THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT Exhibit 10.13 WEREWOLF THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the ?Agreement?) is entered into as of May 29, 2020, by and between PACIFIC WESTERN BANK, a California state chartered bank (?Bank?) and WEREWOLF THERAPEUTICS, INC. (collectively with each of the other Persons, if any, that join as a co-Borrower hereunder are collectively referred to as the ?Bor |
|
| February 26, 2021 |
2017 STOCK INCENTIVE PLAN WEREWOLF THERAPEUTICS, INC. Exhibit 10.1 2017 STOCK INCENTIVE PLAN OF WEREWOLF THERAPEUTICS, INC. TABLE OF CONTENTS PAGE 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 2 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Price 3 (d) Duration |
